BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
80 results:

  • 1. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
    Hong SH; Lee YJ; Jang EB; Hwang HJ; Kim ES; Son DH; Park SY; Moon HS; Yoon YE
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203388
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
    Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
    Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience.
    Pehlivan M; Paksoy N; Aydin E; Basaran M; Ekenel M
    Medicine (Baltimore); 2023 Oct; 102(41):e35245. PubMed ID: 37832108
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
    Knudsen S; Hansen A; Foegh M; Petersen S; Mekonnen H; Jia L; Shah P; Martin V; Frykman G; Pili R
    PLoS One; 2023; 18(8):e0290681. PubMed ID: 37647320
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer.
    Hu BQ; Huang JF; Niu K; Zhou J; Wang NN; Liu Y; Chen LW
    Eur J Pharmacol; 2023 Jul; 950():175746. PubMed ID: 37105515
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation.
    Lin J; Chen X; Yu H; Min S; Chen Y; Li Z; Xie X
    Int J Biol Sci; 2022; 18(9):3621-3635. PubMed ID: 35813477
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells.
    Emaldi M; Nunes-Xavier CE
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563753
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma.
    Li J; Zhang Q; Guan Y; Liao D; Jiang D; Xiong H; Zhan H; Pang J
    Cell Death Dis; 2022 May; 13(5):443. PubMed ID: 35525866
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Ranitidine and Risk of Bladder and kidney Cancer: A Population-Based Cohort Study.
    Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
    Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price.
    Kim H; Goodall S; Liew D
    J Med Econ; 2021; 24(1):893-899. PubMed ID: 34259119
    [No Abstract]    [Full Text] [Related]  

  • 11. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]    [Full Text] [Related]  

  • 12. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
    Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation.
    Miranda-Gonçalves V; Lameirinhas A; Macedo-Silva C; Lobo J; C Dias P; Ferreira V; Henrique R; Jerónimo C
    Cells; 2020 Apr; 9(4):. PubMed ID: 32340156
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture
    Pan T; Martinez M; Hubka KM; Song JH; Lin SC; Yu G; Lee YC; Gallick GE; Tu SM; Harrington DA; Farach-Carson MC; Lin SH; Satcher RL
    Mol Cancer Ther; 2020 Jun; 19(6):1266-1278. PubMed ID: 32220969
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Evaluation of Eribulin Combined with Irinotecan for treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Signaling through tumor necrosis receptor 2 induces stem cell marker in CD133
    Bradley JR; Wang J; Bardsley V; Broecker V; Thiru S; Pober JS; Al-Lamki RS
    Am J Transplant; 2020 Sep; 20(9):2380-2391. PubMed ID: 32167668
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Collaborative Molecular Epidemiology Study of Metabolic Dysregulation, DNA Methylation, and Breast Cancer Risk Among Nigerian Women: MEND Study Objectives and Design.
    Akinyemiju T; Salako O; Daramola A; Alatise O; Adeniyi A; Ogun G; Ayandipo O; Olajide T; Olasehinde O; Arowolo O; Adisa A; Afuwape O; Olusanya A; Adegoke A; Ojo A; Tollefsbol T; Arnett D
    J Glob Oncol; 2019 Jun; 5():1-9. PubMed ID: 31194608
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Melatonin protects chronic kidney disease mesenchymal stem cells against senescence via PrP
    Han YS; Kim SM; Lee JH; Jung SK; Noh H; Lee SH
    J Pineal Res; 2019 Jan; 66(1):e12535. PubMed ID: 30372554
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.